Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a complex and debilitating condition that affects a significant number of men globally. By exploring various drug and therapy options, conducting preclinical research, and offering comprehensive therapy development services, our company strives to contribute to the development of safe and efficacious therapeutics for CP/CPPS.
Introduction to Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) refers to a spectrum of disorders characterized by chronic pelvic pain that lasts for at least three months and is associated with various urinary and sexual symptoms. It is classified into two subtypes: inflammatory and non-inflammatory. The inflammatory subtype, previously known as chronic bacterial prostatitis, is characterized by the presence of bacteria or inflammatory cells in the prostate fluid. The non-inflammatory subtype, also known as chronic pelvic pain syndrome, lacks evidence of infection or inflammation in the prostate.
Fig.1 Analysis of the pathogenesis of experimental autoimmune prostatitis (EAP) models induced by different antigens. (Liu Y., et al., 2021)
Therapeutics Development for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Therapy development for CP/CPPS involves a multimodal approach tailored to each specific symptom and need, aimed at relieving pain and improving urinary function.
| Drugs | Targets | Status |
|---|---|---|
| Tamsulosin | Alpha-blockers | Approved |
| Alfuzosin | Alpha-blockers | Approved |
| Corticosteroids | Anti-inflammatory drugs | Approved |
| Botulinum toxin A (BTA) | Nerves for pain transmission | Approved |
Our Services
Our company is actively involved in the development of diagnostics and novel therapies for CP/CPPS. We are exploring innovative approaches, including targeted immunomodulation, neurogenic inflammation modulation, and regenerative medicine, to address the underlying mechanisms of the condition. To delve deeper into our exceptional therapy development services, we extend a warm invitation for you to explore the links provided below.
Chronic prostatitis/chronic pelvic pain syndrome is a complex condition that poses significant challenges in terms of understanding its pathogenesis and developing effective therapies. We conduct extensive preclinical studies using animal models and in vitro models to evaluate the safety and efficacy of potential therapeutic candidates. Our research focuses on understanding the mechanisms of CP/CPPS and identifying new intervention targets to provide you with innovative therapeutic development solutions.
Immunization Animal Models
We offer immunization models, where rats are immunized with prostate antigens such as prostate-specific antigen (PSA), prostate-specific steroid-binding protein (PSBP), or prostate acid phosphatase (PAP) in complete Freund's adjuvant (CFA).
Spontaneous Prostatitis Models
Our company recognizes the importance of studying spontaneous prostatitis, which occurs naturally in certain rodent strains. We offer services for studying spontaneous prostatitis in rat strains such as Copenhagen, Wistar, Lewis, Sprague-Dawley, and Copenhagen x Fischer.
Hormone-Induced Prostatitis Models
By treating rats with neonatal 17β-oestradiol followed by adult testosterone therapeutics, we can increase the incidence and severity of prostatitis, characterized by mononuclear infiltration, edema, and fibrosis of the prostate tissue.
Autoimmune Prostatitis Mouse Models
Our company offers mouse models of autoimmune prostatitis. Mouse strains such as SJL, AJ, BALB/c, C57BL6, and C57BL6 lpr can be immunized with prostate extract plus adjuvant to induce varying degrees of prostatitis.
Our company specializes in the development of primary cell cultures derived from prostate tissue samples. We also provide access to a variety of immortalized cell lines relevant to CP/CPPS, such as prostate epithelial cell lines (e.g., RWPE-1) and immune cell lines (e.g., THP-1).
Organoids are self-organized 3D structures derived from stem cells or tissue-specific progenitors that closely resemble the architecture and function of the organ from which they originate. We specialize in the generation of prostate organoids from patient-derived samples or immortalized cell lines.
Our team of experts utilizes state-of-the-art technologies and expertise in drug development to design and optimize therapeutic compounds for CP/CPPS. In addition to the extensive array of services and models discussed earlier, our company excels in creating personalized solutions and designing disease models that are precisely tailored to your specific needs. We take immense pride in our capacity to adapt and customize our offerings to cater to the individual requirements of each client. If our comprehensive range of services has captured your interest, we wholeheartedly urge you to reach out to us without any hesitation.
References
- Liu Yuqian, et al. "Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy." International Urology and Nephrology 53 (2021): 607-618.
- Polackwich, A. S., and D. A. Shoskes. "Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy." Prostate Cancer and Prostatic Diseases 19.2 (2016): 132-138.